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Purpose: The plasminogen system, which includes tissue type plasminogen activator (tPA), 
urokinase type plasminogen activator (uPA), and their main inhibitor, plasminogen 
activator inhibitor type 1 (PAI-1), plays a major role in both fibrinolysis and tissue 
remodeling. This study compares the levels oftPA, uPA, and PAI-1 at the groin and ankle 
in normal and varicose greater saphenous vein (GSV). 
Methods: GSV was collected from patients undergoing varicose vein (VV) removal and from 
normal vein (NV) from arterial bypass procedures. Portions of the GSV at the groin and 
the ankle were minced and placed in serum-free media for 48 hours. Assays of the 
supernatants were obtained for tPA, uPA, and PAI-1 protein by enzyme-linked immu- 
nosorbent assay. Cyclohexamide and actinomycin D were also added to the media of the VV 
tissue explant supernatants to inhibit protein and RNA synthesis, respectively. 
Results: Levels oftPA were significantly higher at the groin (11 + 2) than the ankle (5 + 1) 
in the VV (p < 0.005), and this trend was also seen in the NV (groin 10 + 2 and ankle 
7 + 3). Levels of~uPA were significantly higher in the groin VV (14 + 4.3) than in NV 
(3.0 _+ 0.8, p < 0.05). This difference, although not statistically significant, applied to the 
ankle as well (VV 14.5 + 6.3 and NV 5.3 + 2.7). No significant difference was seen between 
NV and VV for PAI-1 (N-V, groin 155 + 73 and ankle 113 + 53, VV, groin 161 _+ 20 and 
ankle 142 + 38) or tPA. Inhibitor studies revealed no significant difference among control, 
cyclohexamide, and actinomycin D supernatants for tPA, suggesting release of protein 
rather than active synthesis. In contrast, inhibitor supernatants were significantly ower for 
uPA and PAL 1 than control supernatants (p < 0.05), suggesting that uPA and PAI-1 were 
actively synthesized. 
Conclusions: In the tissue explant supernatant model uPA and PAI-1 are actively 
synthesized, but tPA is not. Levels of PAL 1 were comparable in all four groups. Levels of 
uPA in the varicose GSV were higher than in NV, suggesting a role for uPA in the 
pathologic makeup of VV. Levels oftPA were higher at the groin versus the ankle position, 
potentially explaining the previously described increased fibrinolytic activity seen at the 
groin. (J Vasc Surg 1996;24:719-24.) 
Varicose veins (W)  are present in 30% to 60% of 
adults and increase in incidence with age. ~ At least 
three current heories explain the pathogenesis ofW 
formation including valvular incompetence, multiple 
arteriovenous communications leading to increased 
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flow, and venous wall weakness .2Several investigators 
have evaluated the collagen content of W to explore 
the theory of wall weakness. This evaluation has 
produced conflicting reports of decreased collagen 
content in W by some authors, 3,4 whereas others 
have found increased amounts)  ,6The plasminogen 
activation system is involved with tissue remodeling 
through its ability to degrade extracellular matrix 
components and therefore may play a role in W 
formation. 
Rose and Ahmed 7 examined the histologic char- 
acteristics of  normal and W and found increased 
fibrous tissue especially in the muscle layer, which 
caused separation and interruption of the muscle cell 
pattern and subintimal deposition of  collagen in W.  
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Transmission electron microscopy revealed increased 
fibrous tissue in VV separating the muscle fibers, and 
many of the collagen fibers lost their regular bundle 
formation. Some of the collagen appeared to have 
been ingested by the muscle cells, suggesting that 
these cells had taken on phagocytic properties and 
that many of the elastic fibers were scattered and 
broken. The authors believed that the altered tissue 
remodeling exhibited by fragmentation f the elastin 
and muscle cell separation may interfere with contrac- 
tion of the veins and thereby contribute to wall 
weakness. 
Genetic factors have also been implicated in thc 
pathogenesis of venous wall weakness. Cornu- 
Thenard et al. s studied the families of patients with 
VV and found that the risk of having VV for the 
children was 90% when both parents were affected, 
25% for male patients and 62% for female patients 
when one parent had this disease, and 20% when 
neither parent was affected. Further support for a 
genetic influence stems from the work of Manrel et 
al., 6 who measured the levels of various types of 
collagen in normal veins, normal appearing segments 
of veins from paticnts with VV, and dilated segments 
of VV. They found that VV had a higher content of 
collagen than normal vein and that no significant 
differences were present in the collagen content of 
normal appcaring segments and dilated areas of vein 
from patients with VV. This finding suggests that 
there may be a general predisposition to varicosity 
formation throughout the venous ystem of suscep- 
tible individuals and that mechanical or other factors 
may influence the actual location of the varicosities. 
The fibrinolytic potential of the venous ystem is 
currently an area of research interest. Several investi- 
gators have studied the fibrinolytic potential of 
greater saphenous veins (GSV) and have found a 
significantly higher level of fibrinolytic activity in the 
groin area when compared with the ankle in VV. 9,~° 
These results were also observed in specimens ob- 
tained from legs amputated because of arterial insuf- 
ficiency, n The methods used, however, measurcd 
overall fibrinolytic activity by comparing zones oflysis 
on fibrin agar plates rather than the level of each 
specific plasminogen activator. 
There are two different plasminogen activators. 
Tissue type plasminogen activator (tPA) and urokl- 
nasc type plasminogen activator (uPA) convert he 
proenzyme plasminogen into its active form, plasmin. 
Plasmin is important in tissue remodeling and fibrin- 
olysis. Plasminogen activator inhibitor type I (PAI- 1) 
is a major inhibitor of both tPA and uPA. Plasmin 
plays a key role in the degradation fthe extracellular 
matrix by directly digesting matrix proteins and by 
activating the proteolytic matrix metalloprotein- 
ases) 2Breast and lung cancer, which can be thought 
of as unregulated forms of tissue remodeling, exhibit 
elevated levels of uPA. 13 The formation of varicose 
veins requires cxtensive tissue remodeling, and thus 
the kinetics of the plasminogen activators are of 
interest. 
Another important function of plasmin is fibrin- 
olysis. Plasmin degrades fibrin-rich clots after being 
activated by clot-bound tPA. 14 Elevated levels of 
plasma PAId induce a hypercoaguable state by in- 
hibiting the plasminogen activators, and this finding 
has been associated with thrombotic omplications 
such as deep venous thrombosis is and myocardial 
i n fa rc t ion .  16 
To datc, no quantitative data are available on the 
levels oftPA, uPA, and PAI-1 in normal veins (NV) 
and VV. With the method of tissue explant superna- 
tants, the levels of the plasminogen activators and 
PAL 1 in NV and VV at the groin and ankle positions 
have been measured to allow speculation on their 
influence over tissue remodeling and fibrinolysis. 
METHODS 
The following studics were performed with the 
approval of the Institutional Rcview Board of North- 
western University, and all patients gave informed 
consent. Varicose GSV was obtained from patients 
undergoing vein stripping, and normal vein (NV) was 
acquired from operations with GSV bypass grafts for 
lower extremity arterial insufficiency. Samples from 
both the anlde and groin were obtained from all the 
patients with W,  whereas NV specimens were col- 
lected from one site only from each patient. W were 
obtained with a plastic stripper to remove the GSV 
from the groin to the ankle in patients with docu- 
mented saphenofemoral reflux and symptomatic vari- 
cosities in one or both legs. NV specimens were 
obtained from patients without any visible varicosities 
or history of venous disease. 
Tissue explant supernatants. In the operating 
room, specimens were placed on ice in holding media 
(Dulbecco's Modified Eagle's Medium, Ham's F- 12, 
16% fetal bovine serum, penicillin/streptomycin, and 
amphotericin B) and were processed within 1 to 
2 hours. Using sterile technique, the tissue was 
washed with phosphate-buffered saline solution to 
remove residual thrombus, minced into 1 x 1 mm 
squares, weighed, and placed into 4 ml of Ros- 
well Park Memorial Institute media with peni- 
cillin/streptomycin per1 gm of tissue. The specimens 
were incubated at 37 ° C with 5% CO 2 for 48 hours. 
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The media nd tissue were removed from the culture 
flasks and centrifuged, and the supernatant was ali- 
quoted and stored at -80 ° C. Protein and RNA 
syntheses were inhibited, respectively, by cyclohexa- 
mide (25 gg/ml) and actinomycin D (5 gg/ml)in the 
W supernatants. The inhibitors were dissolved in 
alcohol and added to the Roswell Park Memorial 
Institute media t time zero and were in contact with 
the tissue for 48 hours. Control flasks contained tissue 
from the same patient placed in Roswell Park Memo- 
fial Institute media plus alcohol only. Normal speci- 
mens were not used in inhibitor experiments because 
of sample size limitations. 
Quantification of tPA, uPA, and PAI-1. Total 
tPA, uPA, and PAI-1 antigens were quantitated with 
TintElize tPA, TintElize uEA, and TintElize PAI-1 
(Biopool International, Ventura, Calif.), respectively. 
These enzyme-linked immunosorbent assays recog- 
nize all forms oftPA, uEA, and PAL 1. Manufacturer's 
instructions for nonplasma samples were followed, 
and interassay variability was approximately 5%. 
Statistics. Unpaired and paired Student's t tests 
were performed, and results were reported as signifi- 
cant at the p < 0.05 level. Results are reported as the 
mean _+ SEM. 
RESULTS 
Tissue explant supernatants. Assays of PAI-1, 
tEA, and uPA were obtained in 48-hour supernatants 
from both the ankle and groin positions of eight 
patients with VV, who had an average age of 48 + 3 
years. Normal GSV at the groin location was obtained 
from seven patients with an average age of 62 + 4 
years and at the ankle position from five patients 
whose average age was 73 + 5 years. Results of these 
assays are reported in Table I. No significant differ- 
ences were found in PAI-1 levels in any of the four 
groups. Levels of tEA were twofold higher at the groin 
position as compared with the ankle in the VV 
specimens (p < 0.005). In the normal specimens tEA 
levels were higher at the groin than the ankle, but the 
difference was not statistically significant. No signifi- 
cant differences were found between VV and NV tPA 
levels at either the groin or ankle positions. 
In contrast o these findings, uPA levels at the 
groin were approximately fivefold higher in VV as 
compared with NV supernatants (p< 0.05). Al- 
though the differences were not significant, this trend 
was also observed at the ankle position between VV 
and NV samples. No significant differences were 
found in uPA levels when the locations of the samples 
were compared. 
Inhibitor studies were performed on the eight 
W specimens at both the ankle and groin positions 
to determine whether the proteins were being ac- 
tively synthesized in the tissue explant supernatant 
model. Cyclohexamide was used to inhibit protein 
synthesis, and actinomycin D was used to inhibit 
RNA synthesis. Results of these assays are reported 
in Table II. No significant differences were found in 
tPA levels in control versus treated supernatants, 
suggesting that tPA is released :into the medium and 
is not actively synthesized in the tissue explant su- 
pernatant model. In contrast, ]both uPA and PAI-1 
control groups were significantly higher than treated 
supernatants, suggesting that these proteins were 
actively synthesized in the tissue explant supernatant 
model. Furthermore no significant differences were 
found between the levels of uPA or PAL1 in the 
actinomycin D versus the cyclohexamide superna- 
rants, suggesting that the rate of protein synthesis of 
these two molecules was controlled at the level of 
transcription. Levels of uPA in control supernatants 
were approximately nine- to tenfold higher than in 
the treated supernatants, whereas PAL1 control su- 
pernatants were five- to 14-fold higher than treated 
supernatants. 
DISCUSSION 
Previous studies demonstrated an increased fi- 
brinolytic activity in normal n and varicose 9'1° GSV 
at the groin versus the ankle position but were 
unable to identify the responsible protease. Our 
findings uggest that tPA may be responsible for this 
previously described ifference. There was approxi- 
mately a twofold increase in tPA levels in groin W 
compared with ankle GSV when paired samples from 
eight different patients were compared (p < 0.005). 
Normally, tPA is produced by endothelial cells, and 
the amount produced varies with the location of the 
endothelial cellsJ 7 Our findings indicate that the 
venous groin specimens contained more tPA than 
the ankle samples, possibly suggesting that groin 
endothelial cells store more tEA than those at the 
ankle. Normal GSV obtained from two different sets 
of patients at the groin and ankle positions followed 
this pattern as well, although the difference was not 
statistically significant, perhaps because of the small 
sample sizes. Individual variation in tPA levels was 
observed in all the groups, with a range of 5 to 15 
ng/ml observed in the groin VV. The use of paired 
specimens in the VV samples decreased the differ- 
ences introduced by individual variation and may 
explain why a statistically significant difference was 
seen in the VV groups but not the NV specimens. 
No significant differences were found in uPA or 
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Table I. Levels of tPA, uPA, and PAI-1 in normal and varicose GSV at the groin and ankle positions 
NV groin (n = 7) NV ankle (n = 5) VV groin (n = 8) VV  ankle (n = 8) 
tPA (ng/ml) 10 ± 2 7 ± 3 11 ± 2* 5 ± 1" 
uPA (ng/ml) 3.0 ± 0.8 t 5.3 ± 2.7 14.3 ± 4.3 t 14.5 ± 6.3 
PAL1 (ng/rrd) 155 ± 73 113 ± 53 161 + 20 142 ± 38 
All values mean ± SEM. 
*p < 0.005. 
tP < 0.05. 
Table II. Levels oftPA, uPA, and PAI-1 in control versus treated supernatant groups in groin and 
ankle VV 
Groin (n = 8) Ankle (n = 8) 
Control Cyclohexamide Actinomycin D Control Cyclohexamide Actinomycin D
tPA (ng/ml) 
uPA (ng/ml) 
PAl- 1 (ng/ml 
11±2 11±2 11±2 5±0 5±1 5±0 
11.1±2.2" 1.2±0.2" 1.2±0.2" 13.9±4.6{ 1.4±0.3~ 1.4±0.3{ 
178±24" 13±1" 15±2" 130±355 24±45 19±55 
All values mean + SEM. 
*p < 0.005. 
tP < 0.05. 
Sp < 0.01. 
PAId levels when the groin and ankle positions were 
compared in these specimens. 
Comparisons between ormal and varicose speci- 
mens revealed a significantly higher level of uPA in 
groin W versus NV (p > 0.05). This trend was also 
observed at the ankle position; however, the differ- 
ence was not significant, perhaps because of the small 
sample size of five in the anlde NV group. Overall, 
levels of uPA were approximately three- to fivefold 
higher in W than NV, whereas no significant differ- 
ences were observed in tPA and PALl levels. This 
finding suggests that uPA may be involved in the 
pathogenesis of W formation, possibly through its 
ability to activate plasmin. Both uPA and plasmin are 
the principal proteases that activate the latent matrix 
metalloproteinases, including collagenase and elas- 
tase. 12 Thus, an increased uPA level may lead to 
enhanced breakdown of collagen and elastin. On 
histologic evaluation VV exhibit fragmented elastin 
and increased placement in the media of both struc- 
turally normal and abnormal collagen. 7 Activities of 
various enzymes in normal and varicose veins have 
previously been studied. Niebes and Laszt ~8 evaluated 
enzymes involved in mucopolysaccharide metabolism 
and found increased activities of hyaluronidase, aryl- 
sulfatase, and glucosaminidase in VV compared with 
those in NV tissue. Urbanova nd Prerovsky 19 studied 
hydrolytic enzymes and showed elevations in acid 
phosphatase and lactate dehydrogenase in VV. In 
contrast, Gandhi et alJ found no significant differ- 
ences between varicose and normal vein gelatinolytic, 
caseinolytic, or elastolytic activities but found in- 
creased collagen and decreased elastin content in VV. 
These findings are consistent with alterations intissue 
remodeling. It is more difficult, however, to explain 
the observations offragmented elastin 7 and decreased 
elastin content in W but no difference in elastolytic 
activity, s Perhaps elastin is destroyed by mechanisms 
other than an increased elastase activity, or the elastase 
activity is only transiently elevated and then returns to 
baseline in established varicosities. 
Another feature of this disease that has generated 
interest is the observation that the biochemical pro- 
files ofvaricosities and "normal appearing" Segments 
of vein from patients with W are similar. Maurel et 
al. 6 and  Gandhi et al. s both found elevations of 
collagen and decreased levels of elastin s in varicosities 
and in normal segments of vein from patients with W 
compared with that from patients with normal veins. 
Lowell et al. 2° studied varicose tributaries and non- 
varicose greater saphenous vein from the same pa- 
tients and found that maximal contractions in re- 
sponse to potassium chloride, norepinephrine, and 
endothelin were reduced in both varicose and non- 
varicose GSV compared with control segments of 
vein. They also found attenuation ofrelaxation i  the 
two vein groups from patients with W and decreased 
protein content and increased endothelin levels com- 
pared with those in normal vein. Consistent with 
these findings is the work of Blochl-Danm et al., 21 
who studied the responsiveness of superficial hand 
veins to local infusions of noradrenaline in patients 
with primary varicose veins and healthy volunteers. 
They found that patients with W required sign±f±- 
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candy higher doses ofnoradrenaline forhalf-maximal 
venoconstriction than the dose required by a control 
group. Furthermore, the noradrenaline r sponsive- 
ness in varicose veins was not significantly different 
from hand vein responsiveness in the same patient. 
These observations are consistent with the theory that 
there may be a general predisposition tovaricosity 
formation throughout the venous ystem of suscep- 
tible individuals and that mechanical or other factors 
may influence the actual location of the varicosities. In 
this study most of the GSV removed from patients 
with W were normal on gross evaluation. The groin 
area was more likely to be dilated than was the ankle 
location, and yet the uPA levels were similar in both of 
these areas but were elevated when compared with 
veins from normal individuals. Additional research in 
this area may further delineate the mechanisms of 
varicosity formation. 
Of interest is the protein and RNA synthesis 
inhibition studies performed on the W specimens. 
These results showed that uPA and PM-1 were 
actively synthesized in the tissue explant supernatant 
model but that _PA was not. No significant differences 
were found in the levels of uPA and PAL1 in the 
actinomycin D versus the cyclohexamide superna- 
rants, suggesting that he rate of synthesis of these two 
molecules i controlled at the level of transcription. I  
contrast, similar inhibition experiments with tissue 
explant supernatants with normal and aneurysmai 
aorta revealed that PAL 122 was actively synthesized in 
this model but that tPA and uPA were not. z3 We can 
only speculate on why uPA is actively synthesized in 
the W but not the aortic supernatants and whether 
uPA would be actively synthesized in NV superna- 
rants. Further esearch is needed to elucidate these 
biochemical differences between the arterial and 
venous pecimens. 
A potentially confounding factor in this study is 
the differences in the ages of the VV group (48 + 3 
years) compared with the NV group (groin, 62 + 4 
and ankle, 73 + 5 years). Most of the previous work 
dealing with levels of the components of the plas- 
minogen system and age have been performed on 
serum samples with conflicting results. For PAI-1 
some authors have reported an age-related increase in 
serum PAI-1 levels, 24-27 whereas others have found 
this age-related increase only in male 28 or female 
patients, 29and, finally, some researchers report no 
association with serum PAI-1 levels and age. 3°32 
Conflicting data for serum levels of tPA also exist, 
with most of the authors showing an age-related 
increase, 2s27,a2-34 whereas another eport reveals an 
age-related decreases A literature search failed to 
find any data regarding serum uPA levels an d age. This 
report studied levels of various plasminogen system 
components in the venous wall, and no age-related 
differences were noted; however, the number of 
samples was small. We are not aware of any previous 
studies comparing venous wall levels oftPA, uPA, and 
PAI-1 and age. Other researchers have studied tissue 
levels of the plasminogen system and found no 
correlation with age oftPA levels in breast cancer 3s or 
PAI-1 levels in pulmonary adenocarcinoma 36 nd 
brain tumors. 37 Increased levels of uPA, however, 
were associated with increased age in pulmonary 
adenocarcinoma. 36 
Another potentially confounding factor in this 
study relates to the myriad of associations of the 
different plasminogen system components with vari- 
ous disease states and lifestyles. For example, de- 
creased serum PAI-1 levels ihave been found in 
people who consume a diet high in fruits and veg- 
etables 31 and exercise, 38 whereas elevated levels of 
PAI-1 have been associated with familial venous 
thrombosis is and myocardial infarction. 16 Control- 
ling for all these factors would be extremely difficult; 
therefore we cannot rule out the possibility that the 
observed associations in this study may be due to 
other factors. 
Finally, antigen levels oftPA, uPA, and PAl-1 were 
measured in the tissue explant supernatant s udies 
rather than the activity of these proteins caused by 
the instability of these molecules in the tissue cul- 
ture media. PAL1 is thought o be secreted in an 
active unstable form with a half-life of 75 minutes at 
37 ° C. w Both uPA and tPA are secreted in a proen- 
zyme form that is activated by plasmin cleavage. 
Active uPA and tPA in tissue culture media re rapidly 
inhibited by binding to the more abundant PAL 14°; 
therefore, there would be essentially no active com- 
ponents of the plasminogen system at the 48-hour 
time point chosen in this study. 
To summarize, in the tissue explant supernatant 
model uPA and PAI-1 are actively synthesized, but 
tPA is not. Levels of PAI-1 were comparable between 
normal and varicose GSV and between the ankle and 
groin positions. Levels of uPA in the varicose GSV 
were significantly higher than in NV at both the groin 
and ankle positions, suggesting a role for uPA in the 
pathogenesis of W.  Levels oftPA were higher at the 
groin versus the ankle position in W and tended to go 
in that direction with NV, potentially explaining the 
previously described increased fibrinolytic activity 
seen at the groin compared with the ankle level. 
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